Omnia Family Wealth’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Omnia Family Wealth’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-112	Closed	-$6K	–	657
2017 Q3	$6K	Hold	112	–	–	﹤0.01%	328
2017 Q2	$6K	Hold	112	–	–	﹤0.01%	370
2017 Q1	$4K	Hold	112	–	–	﹤0.01%	477
2016 Q4	$3K	Buy	+112	New	+$2.19K	﹤0.01%	554

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Omnia Family Wealth's PTLA Position: Q4 2017 in Review

Omnia Family Wealth sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 112 shares — an estimated $6K sold.

Omnia Family Wealth first reported a position in PTLA in Q4 2016 and held it in 4 quarters. The position peaked at $6K in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

Omnia Family Wealth reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Omnia Family Wealth sold 112 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $6K.
Omnia Family Wealth first reported a position in Portola Pharmaceuticals, Inc. in Q4 2016 and held it in 4 quarters.
Omnia Family Wealth's Portola Pharmaceuticals, Inc. position peaked at $6K in Q3 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Omnia Family Wealth's 13F filing for Q4 2017, filed 2 Feb 2018.